Sign In
Buy NBIX
$175.77
+1.62 (+0.93%)
At Close: Jul 24, 2026
Neurocrine (NBIX) Q2 Revenue Jumps 17%
12:15am, Friday, 01'st Aug 2025
Neurocrine (NBIX) Q2 Revenue Jumps 17%
Neurocrine Biosciences Positioned For Growth And New Potential Blockbusters
08:24am, Thursday, 31'st Jul 2025
Neurocrine Biosciences' Ingrezza still generates most of its total revenues. This is their blockbuster drug. I also believe Ingrezza is well-positioned for future growth with new label additions, and
Neurocrine Biosciences, Inc. (NBIX) Q2 2025 Earnings Call Transcript
08:18pm, Wednesday, 30'th Jul 2025
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants n - Corporate Participant Eiry Wyn Roberts - Corporate Participant Strategic
Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 Earnings
07:01pm, Wednesday, 30'th Jul 2025
Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Stree
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
06:11pm, Wednesday, 30'th Jul 2025
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.98 per share. This compares to earnings of $0.63 per share a year ago.
Neurocrine Biosciences Reports Second Quarter 2025 Financial Results
04:01pm, Wednesday, 30'th Jul 2025
Achieved Total Net Product Sales of $682 Million Representing 17% Year-Over-Year Growth INGREZZA® (valbenazine) Second-Quarter 2025 Net Product Sales of $624 Million and Narrows 2025 Net Product Sale
CPRX vs. NBIX: Which Stock Should Value Investors Buy Now?
12:41pm, Monday, 28'th Jul 2025
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX). But which of these two companies is the best option
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:06am, Wednesday, 23'rd Jul 2025
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition
09:00am, Tuesday, 15'th Jul 2025
Technology-enabled research approach and AI-powered analysis identify unmet needs in patients with congenital adrenal hyperplasia SAN FRANCISCO , July 15, 2025 /PRNewswire/ -- PicnicHealth , a health
Approximately 95% of adult and pediatric patients were exposed to supraphysiologic doses of glucocorticoids and/or experienced elevated androstenedione levels at least once during their treatment jour
Adult and pediatric patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont) achieved clinically meaningful weight reductions Substantial improvements in insulin r
One-year data from CAHtalyst™ Adult study demonstrated lasting reductions in glucocorticoid dose and improvement in clinical outcomes in adults with classic congenital adrenal hyperplasia Results b
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results
04:01pm, Wednesday, 09'th Jul 2025
Conference Call and Webcast Scheduled for Wednesday, July 30 SAN DIEGO , July 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quart
Neurocrine Biosciences: Still A Buy After 30% Uplift Since My Last Coverage
12:40pm, Friday, 04'th Jul 2025
Neurocrine's core assets, INGREZZA and Crenessity, can drive strong revenue growth with robust patent protection and significant market underpenetration. The pharma's pipeline is advancing, with multi
SAN DIEGO , June 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study to evaluate the safety, tolerability, p
